Armed with pos­i­tive ALS da­ta, Amy­lyx scores $30M in fresh fund­ing to com­plete Alzheimer's PhII

Four years af­ter an­nounc­ing them­selves to the biotech world with a new idea for drug­ging neu­rode­gen­er­a­tion, back­ing by the late Hen­ri Ter­meer and $5 mil­lion from Morn­ing­side Ven­ture, the young en­tre­pre­neurs at Amy­lyx are back for round 2.

Morn­ing­side con­tin­ued to lead the $30 mil­lion Se­ries B, with par­tic­i­pa­tion from Ter­meer’s wid­ow, Be­lin­da, and oth­er un­named in­vestors. Hav­ing cel­e­brat­ed a topline Phase II win for its lead pro­gram in amy­otroph­ic lat­er­al scle­ro­sis, Amy­lyx ex­pects the cash to fund talks with reg­u­la­tors as well as a sep­a­rate tri­al for the same drug in Alzheimer’s — for which they had just fin­ished en­rolling.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER